Biofilm defense: Mechanisms and actions of a new class of broad-spectrum antimicrobials

Scientist finds link between antibiotics, bacterial biofilms and chronic infections 

Last month WHO issued a report that warned of an increase of antimicrobial-resistance and the renewed threat of bacterial infections world-wide and called for a concerted effort to develop new and better antimicrobial drugs. A study published on May 22nd in PLOS Pathogens reveals how a new type of anti-microbial substance interferes with biofilms formed by several dangerous bacteria.
When growing on surfaces (including , , heart, or ) many bacteria form so-called biofilms that consist of structured communities of identical bacteria. 65% of human infections are caused by biofilms, and in this configuration bacteria are much more resistant to standard antibiotics. Bob Hancock, from the University of British Columbia, Canada, and colleagues, are working on antimicrobials that inhibit bacterial biofilms. At the center of this study is "1018", a small protein (or peptide) with anti-biofilm activity against a range of different bacteria.
At concentrations that did not affect the "planktonic growth" of free-swimming bacteria, 1018 treatment completely prevented biofilm formation and eradicated mature biofilms in both Gram-negative and Gram-positive bacteria, including the major resistant pathogens Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, and methicillin resistant Staphylococcus aureus (or MRSA).
In their quest to understand the mechanism by which 1018 kills bacteria, and specifically those in biofilms, the researchers reasoned that it had to interfere with a process that was common to different bacterial species. One such process is the wide-spread "stringent stress response" that uses specific mediators called (p)ppGpp to orchestrate the expression of a plethora of genes that help bacteria to cope with changing environments. The scientists hypothesized that 1018 (and possibly other anti-biofilm factors) acted by blocking the stringent response.
They went on to test this by over-producing the mediator (p)ppGpp in biofilm-forming bacteria, and the fact that this made the bacteria more resistant to 1018 suggested that they were on the right track. They then went on to demonstrate that 1018 directly and specifically interacts with (p)ppGpp, triggers the destruction of the mediator, and thereby prevents its role in biofilm formation and maintenance.
The researchers conclude that "the strategy presented here represents a significant advance in the search for new agents that specifically target bacterial biofilms". On this basis, they are working to "take advantage of the opportunity to now develop more active peptides that have even more potent anti-biofilm activity".

Comments

Post a Comment

Popular posts from this blog

Fussy eaters: the favoured food of Salmonella

Image
As antibiotic resistance increases the search for new anti-bacterial treatments becomes more and more important. One way to design anti-bacterials is to find specific biochemical pathways that the bacteria require to survive, and develop drugs that block off these pathways. Some pathways are better targets than others and for  Salmonella bacteria it was thought that pathways dealing with nutrient metabolises would be a lost cause. Salmonella lives in the intestine, which hosts a whole variety of different nutrients, so surely preventing the bacteria from using a specific one wouldn’t cause them much undue distress. It’s been found, however, that as they grow and spread in the inflamed intestine the bacteria are heavily reliant on one particular nutrient: fructose-asparagine. The chemical structure of fructose-asparagine, image from the reference. The importance of fructose-asparagine metabolism was originally discovered durin...
Read more

Timing is key for bacteria surviving antibiotics

For bacteria facing a dose of antibiotics, timing might be the key to evading destruction. In a series of experiments, Princeton researchers found that cells that repaired DNA damaged by antibiotics before resuming growth had a much better chance of surviving treatment. When antibiotics hit a population of bacteria, often a small fraction of "persister" cells survive to pose a threat of recurrent infection. Unlike bacteria with genetic resistance to antibiotics, evidence suggests that persisters stay alive in part by stalling cellular processes targeted by the drugs. In a new study, Princeton researchers examined a class of antibiotics that target bacterial DNA. In bacterial populations, some cells repair damaged DNA before resuming growth, and others resume growth before making repairs. The researchers found that those that make repairs before resuming growth generally are the ones that survive as persisters. The research advances a long-term goal to make ...
Read more

HIV lies dormant in brain?

Image
The HIV virus, which causes AIDS, has long been known to target and disable cells of the immune system, which are responsible for fighting off invading microorganisms and for suppressing malignant cancers. More recently, researchers also learned HIV not only targets immune cells in the bloodstream but also in the brain and spinal cord and that HIV can lie dormant in a person’s body for many years. My mentor, Dr. Habibeh Khoshbouei , has been working on this problem and learned that one consequence of HIV in the brain is that age-related diseases develop much earlier . This includes neurological conditions such as Alzheimer’s and Parkinson’s disease , as well as an increased susceptibility to drug addiction . Our lab wanted to learn why. HIV effects persist despite treatment HIV, the virus that causes AIDS, is shown budding out of an immune cell, which the virus infects and uses to replicate. NIH, via Wi...
Read more